At a glance
- Originator LEO Pharma
- Class Antineoplastics; Vitamins
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 25 Jul 2001 Discontinued-II for Psoriasis in Denmark (Topical)
- 20 Oct 1999 A preclinical study has been added to the Musculoskeletal disorders pharmacodynamics section
- 29 Jan 1997 New profile